Fig. 2: Immunogenicity and efficacy testing of first-generation candidate MV-ZIKV vaccines using a lethal ZIKV African MR766 challenge strain.

a Timeline of vaccination, challenge and viral load determinations. Anti-ZIKV-E-specific (b), and anti-MV-H-specific (c) ELISA IgG EC₅₀ titers of the vaccinated animals are plotted on a graph for all animals at different time points. The mean of triplicate EC₅₀ values is depicted per animal. Mean ± SD is depicted per group. ZIKV neutralization with PRVABC59 Asian strain. FRNT was performed on day 104 (d) and necropsy (i) sera from vaccinated animals and controls. The mean 50% neutralizing titer (FRNT₅₀) of triplicates is plotted for each animal on the graph. The Mean ± SD is depicted per group. e Kaplan–Meier survival curve analysis of vaccinated and control animals post-challenge. ZIKV RNA copies by quantitative polymerase chain reaction (qPCR) in the blood (f), brain (g), and reproductive tract (h). The mean of triplicate RNA copies is depicted per animal. The Mean ± SD is depicted per group. The LOD is 100 copies. Statistics for Fig. 2b–d & f–i were done using the two-way ANOVA with post hoc Tukey HSD test and performed on log-transformed data for each time point. Figure 2e survival curves were analyzed using the log-rank test with a Bonferroni correction. Only significant differences are depicted. P value of 0.1234(ns), 0.0332(*), 0.0021(**), 0.0002(***), <0.0001(****) are depicted accordingly. LOD stands for limit of detection. A horizontal line (—) is used to include all groups below it.